| Literature DB >> 32410682 |
Walter Basso1, Elena Sollberger2,3, Gereon Schares4, Susanne Küker5, Flurin Ardüser3, Gaia Moore-Jones6, Patrik Zanolari3.
Abstract
BACKGROUND: Little is known about the epidemiology of Toxoplasma gondii and Neospora caninum infections in alpacas (Vicugna pacos) and llamas (Lama glama) outside South America. The study aimed to estimate the seroprevalence of T. gondii and N. caninum infections in South American camelids (SAC) in Switzerland, to optimize serological tests for SAC and to identify risk factors, which may favour infection.Entities:
Keywords: Alpaca; ELISA; Immunoblot; Lama glama; Llama; Neosporosis; Toxoplasmosis; Vicugna pacos
Mesh:
Substances:
Year: 2020 PMID: 32410682 PMCID: PMC7227098 DOI: 10.1186/s13071-020-04128-9
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Seroprevalence of T. gondii antibodies in South American camelids
| Country (Region) | SAC species | Test (commercial provider) | Cut-off | No. positive/No. examined | % Positive | Reference |
|---|---|---|---|---|---|---|
| Peru (Lampa, Puno) | Alpaca | IHA (Toxotest, Wiener Lab.) | 1:16 | 89/200 | 44.5 | [ |
| Llama | 38/136 | 27.9 | ||||
| Peru (Canchis, Cusco) | Alpaca | IFAT | 1:50 | 97/272 | 35.7 | [ |
| Peru (Peruvian Andes, Central and South Sierra) | Llama | IFAT Conjugate: anti-llama IgG-FITC (VMRD) + confirmation of positive results by Western blot | 1:50 | 19/43 | 44.2 | [ |
| Vicuna | 11/200 | 5.5 | ||||
| Peru (Puno, South-Eastern Peru) | Alpaca | Immunoblot | 20/675 | 3.0 | [ | |
| Llama | 7/81 | 8.6 | ||||
| Vicuna | 3/114 | 2.6 | ||||
| Peru (Central Sierra) | Alpaca | IHA (Toxotest, Wiener Lab.). | 1:16 | 42/200 | 21.0 | [ |
| Peru (Central Sierra) | Alpaca | IFAT Conjugate: anti-llama IgG-FITC (VMRD) | 1:200 | 22/258 | 8.5 | [ |
| Peru (Melgar, Puno) | Llama | IFAT | 1:200 | 16/107 | 14.9 | [ |
| Peru (Central and South Peruvian Andes) | Alpaca | IFAT Conjugate: anti-llama IgG FITC (VMRD) | 1:200 | 706/2874 | 24.6 | [ |
| Llama | 460/1845 | 24.9 | ||||
| Argentina (Jujuy) | Llama | IFAT Conjugate: anti bovine IgG FITC (Sigma-Aldrich) | 1:50 | 44/308 | 14.3 | [ |
| Chile | Alpaca | IHA (in-house) | 1:16 | 32/447 | 7.2 | [ |
| Chile | Alpaca | MAT | 1:25 | 15/127 | 11.8 | [ |
| Llama | 49/113 | 43.3 | ||||
| USA (Northwest: Oregon, Washington State and Idaho) | Llama | MAT | 1:25 | 95/283 | 33.5 | [ |
| USA Virginia | Alpaca | MAT | 1:25 | 6/16 | 37.5 | [ |
| Germany (Hesse) | Alpaca | Immunoblot | 4/12 | 33.3 | [ | |
| Llama | 10/20 | 50.0 | ||||
| Czech Republic | Alpaca | ELISA (ID Screen Toxoplasmosis indirect multispecies ID.vet) | S/P (%) ≥ 50%a | 1/1 | 100 | [ |
| Llama | 7/8 | 88.0 | ||||
| Alpaca | IFAT Conjugate: anti-llama IgG FITC (VMRD) | 1:50 | 0/1 | 0 | ||
| Llama | 4/8 | 50.0 |
aS/P (%) calculated according to the formula: S/P %= (OD sample/OD positive control) × 100, OD optical density
Abbreviations: cELISA, competitive-inhibition enzyme-linked immunosorbent assay; IFAT, indirect fluorescent antibody test; FITC, fluorescein isothiocyanate conjugate; IHA, indirect hemagglutination; MAT, modified agglutination test
Seroprevalence of N. caninum antibodies in South American camelids
| Country | SAC species | Test (commercial provider) | Cut-off | No. positives/No. examined | % Positives | Reference |
|---|---|---|---|---|---|---|
Peru Highlands, Central and Southern Peru | Alpaca | IFAT conjugate: anti-llama IgG FITC (VMRD) | 1:50 | 39/92 | 42.4 | [ |
| Llama | 1:50 | 39/212 | 18.4 | |||
Peru Highlands, different regions | Alpaca | IFAT conjugate: anti-llama IgG–FITC (VMRD) + confirmation of positive results by Westernblot | 1:50 | 14/78 | 17.9 | [ |
| Llama | 17/73 | 23.3 | ||||
Peru Puno, South-Eastern Peru | Alpaca | Immunoblot | 17/675 | 2.5 | [ | |
| Llama | 1/81 | 1.2 | ||||
| Vicuna | 0/114 | 0 | ||||
Peru Yauli, Central Sierra | Alpaca | IFAT conjugate: anti-llama IgG FITC (VMRD) | 1:100 | 5/175 | 2.9 | [ |
Peru Central and South Peruvian Andes | Alpaca | IFAT conjugate: anti-llama IgG FITC (VMRD) | 1:100 | 425/2874 | 14.8 | [ |
| Llama | 153/1845 | 8.3 | ||||
Peru Arequipa, South Peruvian Andes | Vicuna | ELISA, Chekit Neospora – cELISA (IDEXX) + confirmation of positive results by Westernblot | 2/207 | 1.0 | [ | |
| Alpaca | 2/571 | 0.3 | ||||
| Llama | 0/43 | 0 | ||||
Peru Huancavelica | Llama | IFAT conjugate: anti-llama IgG FITC (VMRD) | 1:100 | 12/98 | 12.2 | [ |
Peru Huancavelica | Alpaca | IFAT | 1:100 | 47/288 | 16.3 | [ |
Argentina Jujuy | Llama | IFAT conjugate: anti bovine IgG FITC (Sigma) | 1:50 | 3/308 | 1.0 | [ |
Australia South | Alpaca | ELISA, | 0/182 | 0 | [ | |
Australia New South Wales and Victoria | Alpaca | ELISA, | %I ≥ 30%a | 3/100 | 3.0 | [ |
Germany Hesse | Alpaca | Immunoblot | 0/12 | 0 | [ | |
| Llama | 0/20 | 0 | ||||
| Czech Republic | Alpaca | ELISA, | %I ≥ 30%a | 0/1 | 0 | [ |
| Llama | 1/8 | 12.5 | ||||
| Alpaca | IFAT conjugate: anti-llama IgG FITC (VMRD) | 1:50 | 0/1 | 0 | ||
| Llama | 1/8 | 12.5 |
cELISA: competitive-inhibition enzyme-linked immunosorbent assay, IFAT: indirect fluorescent antibody test; a %I (% inhibition) calculated according the formula: %I = 100 − (OD sample × 100/mean OD negative control), OD optical density, S/P (%) calculated according to the formula: S/P = (OD sample/OD positive control) × 100; FITC: fluorescein isothiocyanate conjugate
Fig. 1Map of Switzerland showing the distribution of South American camelid (SAC) breeding farms (n = 132) sampled in the study (all dots) and the farms in which N. caninum seropositive SAC were detected (red dots)
Results of receiver operating chraracteristics (ROC) analysis
| ELISA Kit | Optimized ELISA cut-off | AUC | % Relative sensitivity (95% CI) | % Relative specificity (95% CI) | PPV % (95% CI) | NPV % (95% CI) |
|---|---|---|---|---|---|---|
| TOXO-MS | ≥ 36.2 S/P% | 0.97 (0.94–1.00) | 94.5 (87.6–98.2) | 97.9 (92.6–99.7) | 97.7 (92.0–99.3) | 94.9 (88.5–99.4) |
| NCS-MS | ≥ 34.9 S/P% | 0.96 (0.91–1.01) | 89.3 (71.8–97.7) | 100.0 (95.4–NaN) | 100 (86.9–100) | 96.3 (88.8–NaN) |
| NCC | ≤ 78.6 S/N% | 0.97 (0.92–1.01) | 92.9 (76.5–99.1) | 97.4 (91.0–99.7) | 92.9 (77.7–99.1) | 97.4 (90.5–99.7) |
Notes: Relative accuracies of commercial ELISA kits used for detection of antibodies against Toxoplasma gondii (i.e. ID Screen® Toxoplasmosis Indirect ELISA) and N. caninum (i.e. ID Screen® Neospora caninum Indirect Multi-species ELISA and ID Screen® Neospora caninum Competition ELISA) in South American camelids, in relation to N. caninum and T. gondii immunoblots
Abbreviations: TOXO-MS, ID Screen® Toxoplasmosis Indirect; NCS-MS, ID Screen® Neospora caninum Indirect Multi-species ELISA; NCC, ID Screen® Neospora caninum Competition; S/P%, sample-to-positive ratio; S/N%, competition percentage; AUC, area under the ROC curve; CI, confidence interval; TP, true positives; FP, false positives; TN, true negatives; FN, false negatives; PPV, positive predictive value; NPV, negative predictive value; NaN, upper limit of the confidence interval could not be computed
Fig. 2Immunoblot results for antibodies against T. gondii in Swiss South American camelids (SAC). Abbreviations: M, molecular marker; Neg, seronegative Swiss SAC field samples; Pos, seropositive Swiss SAC field samples; PC, positive control (Llama); NC, negative control (Llama); >, 30 kDa band corresponding to SAG-1 T. gondii tachyzoite surface antigen. Samples recognizing the 30 kDa antigenic band were considered positive
Inter-rater agreement (Kappa value) between ELISA kits for detection of antibodies against T. gondii (ID Screen® Toxoplasmosis Indirect) or N. caninum (ID Screen® Neospora caninum indirect multi-species and ID Screen® Neospora caninum Competition) and immunoblot, and between ELISA kits (ID Screen® Neospora caninum Indirect Multi-species and ID Screen® Neospora caninum Competition)
| TOXO-MS (manufacturer’s cut-offs) | TOXO-MS (optimized cut-off) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Positive | Doubtful | Negative | Total | Positive | Doubtful | Negative | Total | |||
| Positive | 80 | 3 | 8 | 91 | 86 | 0 | 5 | 91 | ||
| Doubtful | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Negative | 1 | 0 | 94 | 95 | 2 | 0 | 93 | 95 | ||
| Total | 81 | 3 | 102 | 186 | 88 | 0 | 98 | 186 | ||
| Kappa (κ) | 0.873 | 0.925 | ||||||||
| SE of κ | 0.035 | 0.028 | ||||||||
| 95% CI | 0.804–0.941 | 0.870–0.979 | ||||||||
| Weighted κ | 0.887 | 0.925 | ||||||||
TOXO-MS: ID Screen® Toxoplasmosis Indirect; NCS-MS: ID Screen® Neospora caninum Indirect Multi-species ELISA; NCC: ID Screen® Neospora caninum Competition; SE: Standard Error; CI : Confidence Interval
Fig. 3ELISA results for antibodies against N. caninum on serum samples from a llama experimentally inoculated with 4.8 × 10E6 cell culture-derived N. caninum tachyzoites (Llama 1) and from a control llama inoculated with 5 × 10E4 Vero cells (Llama 2) [30]. a ID Screen® Neospora caninum indirect multi-species, S/P% = sample-to-positive ratio, calculated based on the OD (optical density) of the sample and the positive and negative controls of the kit according to the formula S/P% = (ODsample − ODnegative control/ODpositive control − ODnegative control) × 100. b ID Screen® Neospora caninum Competition, S/N% = competition percentage, calculated according to the formula: S/N% = (ODsample/ODnegative control) × 100
Fig. 4Immunoblot results for antibodies against N. caninum on field serum samples from Swiss South American camelids (SAC). Abbreviations: M, marker; PB, positive control (bovine); PC, positive control (Llama 1); NC, negative control (Llama 2); samples 8–28, Swiss SAC field serum samples; +, positive immunoblot result; −, negative immunoblot result. Bands corresponding to immunodominant N. caninum antigens (17, 29, 30, 33 and 37 kDa) are indicated with *. Samples recognizing two or more immunodominant antigens were considered positive
Fig. 5Immunoblot results for antibodies against N. caninum on serum samples from a llama experimentally inoculated with 4.8 × 10E6 cell culture-derived N. caninum tachyzoites (Llama 1) and from a seronegative control llama inoculated with 5 × 10E4 Vero cells (Llama 2). Abbreviations: M, marker; kDa, kilodaltons; 2–52 (indicated above), days post-inoculation (dpi). Bands corresponding to immunodominant N. caninum antigens (17, 29, 30, 33 and 37 kDa) are indicated with an asterisk. In Llama 1, reaction against the 29 kDa antigen is observed at 12 dpi. From 16 to 52 dpi also further immunodominant antigens are recognized. Samples recognizing two or more immunodominant antigens were considered positive. Llama 2 did not recognize any of the N. caninum immunodominant antigens during the observation period
Fixed effects in generalized linear mixed models to determine potential risk factors for Toxoplasma gondii-seropositivity in Swiss South American camelids
| Model (AIC, model fit) | Variable | Odds ratio (95% CI) | ||
|---|---|---|---|---|
| 1 (155.9) | Intercept | 1.090 (0.390–3.070) | 0.170 | 0.864644 |
| Age (months) | 1.020 (1.010–1.040) | 3.602 | 0.000316*** | |
| 2 (153.4) | Intercept | 0.607 (0.209–1.760) | − 0.919 | 0.358139 |
| Age | 1.021 (1.009–1.030) | 3.497 | 0.000471*** | |
| Sex: male (ref.) | ||||
| Sex: female | 2.924 (1.111–7.690) | 2.174 | 0.029711* | |
| 3 (152.4) | Intercept | 1.228 (0.460–3.278) | 0.410 | 0.681820 |
| Age | 1.024 (1.011–1.036) | 3.707 | 0.000210*** | |
| Cat, past 2 years (ref.) | ||||
| No cat, past 2 years | 0.214 (0.055–0.828) | − 2.233 | 0.025530* | |
| 4 (149.3) | Intercept | 0.692 (0.255–1.880) | − 0.722 | 0.470200 |
| Age | 1.021 (1.009–1.033) | 3.540 | 0.000400*** | |
| Sex: male (ref.) | ||||
| Sex: female | 2.941 (1.164–7.426) | 2.282 | 0.022500* | |
| Cat, past 2 years (ref.) | ||||
| No cat, past 2 years | 0.232 (0.066–0.809) | − 2.293 | 0.021900* |
Notes: Data were analysed by bivariable generalized linear mixed modelling including “Age” (months) as effect modifier and “Farm” as random effects variable in modelling T. gondii-seropositivity. The Akaike information criterion (AIC) was used to characterize the relative model quality
Abbreviation: ref., reference
*P ≤ 0.05, **P ≤ 0.01, ***P < 0.001